Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Akebia Therapeutics (AKBA) over the last 10 years, with Q3 2025 value amounting to $0.0.

  • Akebia Therapeutics' EPS (Basic) rose 10203.94% to $0.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.08, marking a year-over-year increase of 6521.74%. This contributed to the annual value of -$0.33 for FY2024, which is 1879.39% down from last year.
  • Per Akebia Therapeutics' latest filing, its EPS (Basic) stood at $0.0 for Q3 2025, which was up 10203.94% from $0.0 recorded in Q2 2025.
  • Over the past 5 years, Akebia Therapeutics' EPS (Basic) peaked at $0.16 during Q2 2022, and registered a low of -$0.51 during Q2 2021.
  • Moreover, its 5-year median value for EPS (Basic) was -$0.09 (2024), whereas its average is -$0.15.
  • As far as peak fluctuations go, Akebia Therapeutics' EPS (Basic) crashed by 340058.75% in 2024, and later soared by 13333.33% in 2025.
  • Akebia Therapeutics' EPS (Basic) (Quarter) stood at -$0.42 in 2021, then soared by 91.61% to -$0.04 in 2022, then skyrocketed by 109.2% to $0.0 in 2023, then tumbled by 3400.59% to -$0.11 in 2024, then skyrocketed by 101.89% to $0.0 in 2025.
  • Its EPS (Basic) stands at $0.0 for Q3 2025, versus $0.0 for Q2 2025 and $0.03 for Q1 2025.